Clarevia Ventures, a venture capital firm based in Madison, Wisconsin, has expanded its leadership team with the appointment of Margaret Kaczor Andrew as Venture Partner.
The firm, known for backing early-stage scientific and healthcare innovations, said the addition reflects its continued commitment to identifying technologies capable of transforming patient care.
In her new position, Kaczor Andrew will play a central role in discovering and assessing investment opportunities across a broad spectrum of healthcare sectors, including medical devices, clinical technologies, and emerging healthcare platforms.
Bringing Deep Industry Expertise to Early-Stage Innovation
Kaczor Andrew joins Clarevia with more than 15 years of experience spanning healthcare innovation, investment analysis, and the commercialization of medical technologies.
Her expertise is expected to enhance the firm’s ability to recognize promising healthcare solutions at an early stage and support entrepreneurs as they navigate the path toward market adoption.
Her background combines a strong understanding of both clinical needs and financial markets, providing a unique perspective on how innovative technologies can achieve long-term impact within healthcare systems.
A Long Career at William Blair
Before joining Clarevia Ventures, Kaczor Andrew spent 15 years at William Blair, where she served as a partner and sell-side equity research analyst.
During her tenure, she focused extensively on clinical innovation and the market forces that influence the adoption of new healthcare technologies.
Her work involved advising investors, corporate leaders, and healthcare companies on a variety of strategic issues, including fundraising initiatives, competitive positioning, business development opportunities, and market expansion strategies.
Focus on High-Impact Medical Technologies
Throughout her career, Kaczor Andrew has developed significant expertise across multiple healthcare disciplines.
She has shown a particular interest in medical technology solutions designed to address unmet clinical and consumer needs.
Her experience covers a diverse range of specialties, including cardiology, neurology, diabetes management, respiratory care, ophthalmology, aesthetics, and consumer health technology.
This broad exposure is expected to support Clarevia’s efforts to identify innovations with the potential to improve patient outcomes across numerous therapeutic areas.
Clarevia’s Mission to Advance Breakthrough Science
Founded in 1984 and led by Managing Partner Jim Adox, Clarevia Ventures focuses on supporting founders during the earliest stages of company development—often before technologies receive widespread attention from investors.
The firm combines capital investment with operational guidance and strategic support to help transform scientific discoveries into commercially viable healthcare solutions.
Its approach is centered on helping innovators bridge the gap between laboratory breakthroughs and real-world patient impact.
Portfolio Highlights Reflect Healthcare Focus
Over the years, Clarevia Ventures has built a portfolio that reflects its emphasis on advancing healthcare innovation.
Among its notable investments are companies such as HistoSonics, Neurovance, and EarliPoint.
With the addition of Margaret Kaczor Andrew, the firm aims to further strengthen its ability to identify breakthrough healthcare opportunities and support founders working to bring new medical technologies to patients around the world.
